Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | HTR1A | P08908 | 8/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687871 | 0.83 | DRD2 (0.58) | DRD4DRD2HTR1AADRA1DADRA1A | |
| SCHEMBL4935832 | 0.83 | DRD2 (0.58) | DRD4DRD2HTR1AADRA1DADRA1A | |
| SCHEMBL11029655 | 0.83 | HTR1A (0.68) | DRD2HTR1ADRD3HTR2A | |
| SCHEMBL11086815 | 0.83 | HTR1A (0.68) | DRD2HTR1ADRD3HTR2A | |
| Hydrochloric Acid SCHEMBL11089984 | 0.82 | HTR1A (0.67) | DRD2HTR1ADRD3HTR2A | |
| Hydrochloric Acid SCHEMBL11082872 | 0.82 | HTR1A (0.67) | DRD2HTR1ADRD3HTR2A | |
| SCHEMBL11080260 | 0.82 | HTR1A (0.67) | DRD4DRD2HTR1ADRD3HTR2A | |
| Hydrochloric Acid SCHEMBL11083772 | 0.81 | HTR1A (0.66) | DRD2HTR1ADRD3HTR2A | |
| SCHEMBL11080291 | 0.81 | ADRA1A (0.58) | DRD2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL11086388 | 0.81 | ADRA1A (0.58) | DRD2HTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | SLC6A3, ADRB3, PRLHR | DRD4 26/4885DRD2 8/4885HTR1A 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.